Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

365 Press Releases
DateTitleCompany
27 Apr 16 VTU Technology and Boehringer Ingelheim strengthen their global microbial technology collaboration VTU Technology and Boehringer Ingelheim,
Published by
VTU Technology
19 Apr 16 Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology Boehringer Ingelheim ,
Published by
PharmiWeb.com
13 Apr 16 Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
13 Apr 16 Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced NSCLC published in The Lancet Oncology Boehringer Ingelheim,
Published by
Business Wire
11 Apr 16 Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy Boehringer Ingelheim ,
Published by
PharmiWeb.com
06 Apr 16 Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations Boehringer Ingelheim ,
Published by
PharmiWeb.com
04 Apr 16 Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations Boehringer Ingelheim,
Published by
Business Wire
01 Apr 16 FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray for COPD Health-Related Quality of Life Boehringer Ingelheim ,
Published by
PharmiWeb.com
29 Mar 16 FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim's STIOLTO RESPIMAT for COPD Health-Related Quality of Life Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
23 Mar 16 Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate) Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
15 Mar 16 Boehringer Ingelheim Cares Foundation and AmeriCares Launch Health Coach Program for the Uninsured Boehringer Ingelheim Cares Foundation,
Published by
PR Newswire
10 Mar 16 New Analyses: Adding SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Effective for Uncontrolled Asthma – Regardless of Allergy Subtype Boehringer Ingelheim,
Published by
PharmiWeb.com
10 Mar 16 Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate), Now Stocked in More Than 2,200 Hospitals Boehringer Ingelheim,
Published by
PharmiWeb.com
10 Mar 16 Boehringer Ingelheim Chooses Genedata Selector for Cell Line Development and Cell Culture Optimization Boehringer Ingelheim ,
Published by
PharmiWeb.com
08 Mar 16 New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma – Regardless of Allergy Subtype1,2,3 Boehringer Ingelheim,
Published by
PharmiWeb.com
07 Mar 16 AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds Boehringer Ingelheim,
Published by
Business Wire
03 Mar 16 European Committee for Medicinal Products for Human Use recommends approval of Giotrif® (afatinib) for advanced squamous cell cancer of the lung Boehringer Ingelheim,
Published by
PharmiWeb.com
26 Feb 16 New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations Boehringer Ingelheim ,
Published by
PharmiWeb.com
05 Feb 16 SPIRIVA® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents Boehringer Ingelheim ,
Published by
PharmiWeb.com
05 Feb 16 SPIRIVA® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents Boehringer Ingelheim,
Published by
PharmiWeb.com
27 Jan 16 Boehringer Ingelheim is Pleased to Welcome Green Light from the National Institute for Health and Care Excellence (NICE) for Its Medicine for Rare Lung Disease. Boehringer Ingelheim,
Published by
Business Wire
27 Jan 16 Idiopathic Pulmonary Fibrosis (IPF): OFEV?® (nintedanib) is recommended for use within the NHS by the National Institute for Health and Care Excellence (NICE) Boehringer Ingelheim,
Published by
Business Wire
17 Feb 16 Praxbind®? (idarucizumab) reimbursed in England, Ireland and Wales Boehringer Ingelheim,
Published by
Business Wire
19 Feb 16 Praxbind®▼ (idarucizumab) reimbursed in England, Ireland and Wales Boehringer Ingelheim ,
Published by
PharmiWeb.com
18 Dec 15 Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress Boehringer Ingelheim ,
Published by
PharmiWeb.com
27 Jan 16 Boehringer Ingelheim’s Giotrif® (afatinib) demonstrated superiority to gefitinib in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer Boehringer Ingelheim,
Published by
Business Wire
29 Jan 16 Idiopathic Pulmonary Fibrosis (IPF): OFEV▼® (nintedanib) is recommended for use within the NHS by the National Institute for Health and Care Excellence (NICE) Boehringer Ingelheim ,
Published by
PharmiWeb.com
21 Dec 15 Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer Boehringer Ingelheim,
Published by
Business Wire
12 Jan 16 Type 2 diabetes: All Wales Medicines Strategy Group recommends Jardiance®? (empagliflozin) as an option for patients with type 2 diabetes in Wales Boehringer Ingelheim,
Published by
Business Wire
17 Jan 16 Type 2 diabetes: All Wales Medicines Strategy Group recommends Jardiance®▼ (empagliflozin) as an option for patients with type 2 diabetes in Wales Boehringer Ingelheim ,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.